Literature DB >> 2369706

Node-negative minimal invasive breast cancer patients are not candidates for routine systemic adjuvant therapy.

D Rosner1, W W Lane.   

Abstract

Ninety-one patients with invasive breast carcinoma with a diameter of 1 cm or less and histologically negative axillary nodes were treated between 1976 and 1986 with radical surgery alone (67), or with conservative surgery (24). Cases were analyzed in relation to tumor size, steroid receptors, histologic and nuclear grade, age, and type of therapy, none of which showed a significant relationship to relapse or survival. There were 22% well-differentiated, 20% moderately differentiated, and 56% poorly differentiated or anaplastic tumors. Estimated disease-free survival (DFS) for this group was 91% at 7 years, and overall survival 96% for the same period. There were five relapses (all among poorly differentiated tumors) and three deaths unrelated to breast cancer. With the three deaths censored, 100% of the well-differentiated and moderately differentiated tumors were disease-free at 7 years versus 91% for poorly differentiated and anaplastic tumors (P = 0.076). These data suggest that node-negative patients with minimal invasive breast cancer are highly curable by primary surgical therapy alone, and the authors believe that these patients are not appropriate candidates for adjuvant therapy until such time as subgroups at high risk of recurrence can be identified.

Entities:  

Mesh:

Year:  1990        PMID: 2369706     DOI: 10.1002/1097-0142(19900715)66:2<199::aid-cncr2820660202>3.0.co;2-l

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  Nonpalpable invasive breast cancer.

Authors:  M C Wilhelm; S B Edge; D D Cole; E deParedes; H F Frierson
Journal:  Ann Surg       Date:  1991-06       Impact factor: 12.969

2.  Will screening for breast cancer reduce mortality? Evidence from the first year of screening in Avon.

Authors:  S Nicholson; A J Webb; B Coghlan; J R Farndon; J S Armstrong; J D Davies
Journal:  Ann R Coll Surg Engl       Date:  1993-01       Impact factor: 1.891

3.  Long term adjuvant therapy for primary breast cancer.

Authors:  R D Bulbrook
Journal:  BMJ       Date:  1996-02-17

4.  Predicting recurrence in axillary-node negative breast cancer patients.

Authors:  D Rosner; W W Lane
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

5.  The relationship between lymph node metastases and DNA-ploidy status as prognostic factors in invasive breast cancer.

Authors:  M Noguchi; N Ohta; N Koyasaki; T Taniya; I Miyazaki; Y Mizukami
Journal:  Surg Today       Date:  1992       Impact factor: 2.549

6.  Quantitative analysis of mutant p53 protein in breast tumor cytosols and study of its association with other biochemical prognostic indicators in breast cancer.

Authors:  M A Levesque; E P Diamandis; H Yu; D J Sutherland
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

7.  Minimal breast cancer: evaluation of histology and biological marker expression.

Authors:  E A Dublin; R R Millis; P Smith; L G Bobrow
Journal:  Br J Cancer       Date:  1999-07       Impact factor: 7.640

8.  Morphometrical malignancy grading is a valuable prognostic factor in invasive ductal breast cancer.

Authors:  P Kronqvist; T Kuopio; P Jalava; Y Collan
Journal:  Br J Cancer       Date:  2002-11-18       Impact factor: 7.640

9.  Prognosis of younger and older patients with early breast cancer.

Authors:  P G Peer; A L Verbeek; M Mravunac; J H Hendriks; R Holland
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.